Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Axon Enterprise Inc. Stock Sheds 5.7%, Underperforms Peers

Axon Enterprise Inc. Stock Sheds 5.7%, Underperforms Peers

Dow JonesDow Jones2026/08/31 20:33

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Axon Enterprise Inc. shed 5.7% to $566.56 on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.3% to 7,686.14 and Dow Jones Industrial Average falling 0.7% to 53,185.90.

This was the stock's second consecutive day of losses.

Axon Enterprise Inc. closed 28.5% below its 52-week high of $792.16, which the company achieved on September 23rd.

The stock underperformed when compared to some of its peers, as Motorola Solutions Inc. fell 0.1% to $485.30, Sturm Ruger & Co. rose 1.9% to $37.97.

Trading volume totaled 1.1 million, compared to the 50-day average of 972,003.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

August 31, 2026 16:33 ET (20:33 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss